ReviewBrazilian journal of otorhinolaryngology
Global research trends and hotspot evolution analysis of immunotherapy for allergic rhinitis: a multi-dimensional exploration based on bibliometrics.
Review in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study employs bibliometric methods to analyze global research trends and the evolution of hotspots in the field of Allergic Rhinitis (AR) immunotherapy between 2010 and 2024.
methodsA comprehensive search was conducted in the Web of Science Core Collection database for relevant literature published from 2010 to 2024. VOSviewer and CiteSpace were utilized to perform analyses on country/institutional collaboration, keyword co-occurrence and clustering, and citation bursts for the final set of 2470 included publications.
resultsThe annual global publication output demonstrated a steady growth trend. The United States, China, and major European countries emerged as the core research contributors. The evolution of research hotspots revealed a distinct "three-polar pattern": a transition in treatment from traditional immunotherapy towards biologics, notably omalizumab and dupilumab; an upgrade in diagnosis from crude allergen extract testing to molecular component-resolved techniques; and the integration of guidelines, digital health, and patient-reported outcomes to form a closed-loop management system.
conclusionThis study identifies a comprehensive shift within the AR immunotherapy field towards precision medicine. Future efforts should focus on real-world evidence generation for biologics, the translation of biomarkers into clinical practice, and cost-effectiveness evaluations, aiming to establish a "precise diagnosis-targeted intervention-dynamic management" clinical pathway. LEVEL OF EVIDENCE: Level 1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.